MP Materials reports smaller Q2 loss as rare earth production surges 119%, boosted by government deals and rising demand.
Decades after 9/11, advanced DNA testing identifies three more victims, providing closure to families and highlighting the role of science in honoring the tragedy's victims.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
MP Materials reports smaller Q2 loss as rare earth production surges 119%, boosted by government deals and rising demand.
Decades after 9/11, advanced DNA testing identifies three more victims, providing closure to families and highlighting the role of science in honoring the tragedy's victims.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.